6/12
02:05 pm
pdsb
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Medium
Report
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
6/12
11:01 am
pdsb
PDS Biotechnology Co. (NASDAQ: PDSB) had its price target lowered by analysts at B. Riley from $11.00 to $9.00. They now have a "buy" rating on the stock.
Medium
Report
PDS Biotechnology Co. (NASDAQ: PDSB) had its price target lowered by analysts at B. Riley from $11.00 to $9.00. They now have a "buy" rating on the stock.
6/12
08:04 am
pdsb
PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer [Yahoo! Finance]
Medium
Report
PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer [Yahoo! Finance]
6/12
08:00 am
pdsb
PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer
Medium
Report
PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer
5/15
10:29 am
pdsb
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Low
Report
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
5/15
08:20 am
pdsb
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results [Yahoo! Finance]
Medium
Report
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results [Yahoo! Finance]
5/15
08:00 am
pdsb
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results
High
Report
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results
5/9
05:46 pm
pdsb
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
Medium
Report
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
5/9
03:39 pm
pdsb
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Low
Report
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
5/9
12:11 pm
pdsb
PDS Biotechnology Co. (NASDAQ: PDSB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
PDS Biotechnology Co. (NASDAQ: PDSB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
5/9
08:00 am
pdsb
PDS Biotech to Participate in Upcoming May 2024 Investor Conferences
Medium
Report
PDS Biotech to Participate in Upcoming May 2024 Investor Conferences
5/7
08:00 am
pdsb
PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024
Low
Report
PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024
5/3
08:09 am
pdsb
PDS Biotechnology Announces Details of Virtual KOL Event [Yahoo! Finance]
Low
Report
PDS Biotechnology Announces Details of Virtual KOL Event [Yahoo! Finance]
5/3
08:00 am
pdsb
PDS Biotechnology Announces Details of Virtual KOL Event
Low
Report
PDS Biotechnology Announces Details of Virtual KOL Event
5/2
08:08 am
pdsb
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer [Yahoo! Finance]
Low
Report
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer [Yahoo! Finance]
5/2
08:00 am
pdsb
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer
Low
Report
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer
4/29
10:11 am
pdsb
PDS Biotechnology: Entering A Holding Pattern While Cash Remains A Concern (Rating Downgrade) [Seeking Alpha]
Medium
Report
PDS Biotechnology: Entering A Holding Pattern While Cash Remains A Concern (Rating Downgrade) [Seeking Alpha]
4/23
08:04 am
pdsb
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer [Yahoo! Finance]
Medium
Report
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer [Yahoo! Finance]
4/23
08:00 am
pdsb
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
High
Report
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
3/30
09:01 am
pdsb
PDS Biotechnology Corporation's (NASDAQ:PDSB) market cap dropped US$1.5m last week; individual investors who hold 59% were hit as were institutions [Yahoo! Finance]
Low
Report
PDS Biotechnology Corporation's (NASDAQ:PDSB) market cap dropped US$1.5m last week; individual investors who hold 59% were hit as were institutions [Yahoo! Finance]
3/28
10:34 am
pdsb
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/27
10:57 am
pdsb
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Low
Report
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
3/27
07:39 am
pdsb
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results [Yahoo! Finance]
High
Report
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results [Yahoo! Finance]
3/27
07:30 am
pdsb
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
High
Report
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
3/21
11:58 am
pdsb
NetScientific: Significant Advancement with Strategic Goals [Yahoo! Finance]
Low
Report
NetScientific: Significant Advancement with Strategic Goals [Yahoo! Finance]